Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares Under 10b5-1 Trading Plan

Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics (ELVN) at a weighted average price of $23.7399, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, sold 1,270 shares of common stock on May 16, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on July 17, 2023.
• The weighted average sale price was $23.7399, with individual transactions ranging from $23.525 to $24.035.
• Following the transaction, Heyman directly owns 135,885 shares.
• He also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 28,567 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine transaction under a pre-existing trading plan. It doesn't inherently reflect positive or negative views on the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for corporate insiders to set up 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The sale itself may not be indicative of the company's performance or future prospects.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates